Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

223.99USD
18 Aug 2017
Change (% chg)

$-0.78 (-0.35%)
Prev Close
$224.77
Open
$224.40
Day's High
$225.62
Day's Low
$223.15
Volume
446,493
Avg. Vol
506,477
52-wk High
$256.78
52-wk Low
$184.58

AGN.N

Chart for AGN.N

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $74,881.24
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.25

Financials

  AGN.N Industry Sector
P/E (TTM): -- 30.61 31.81
EPS (TTM): -11.66 -- --
ROI: -3.08 14.48 14.02
ROE: -5.61 15.57 15.34

UPDATE 2-Israel's Teva seeks partners for new drugs to relieve pressure

* Speeding up divestment plans - sources (Adds context, TPG no comment)

16 Aug 2017

Israel's Teva seeks partners for new drugs to relieve pressure

JERUSALEM/LONDON/FRANKFURT Teva Pharmaceutical Industries is looking to team up with other drugmakers to fund some of its development pipeline as it struggles with debts and expiring patents.

16 Aug 2017

BRIEF-Allergan says as part of internal optimization restructuring programs, co intends to eliminate about 400 positions - SEC Filing‍​

* Allergan Plc - As part of internal optimization restructuring programs, co intends to eliminate about 400 positions - Sec Filing‍​

09 Aug 2017

BRIEF-FDA approves Medicines360's SNDA for Liletta to prevent pregnancy for up to four years

* FDA approves Medicines360's SNDA for Liletta (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to four years

07 Aug 2017

BRIEF-Allergan Plc Q2 revenue $4.0 billion

* Allergan reports continued strong execution in second quarter 2017 with 9% increase in GAAP net revenues to $4.0 billion

03 Aug 2017

Botox-maker Allergan's quarterly profit beats estimates

Botox-maker Allergan Plc reported a better-than-expected quarterly profit, helped by strength in its medical aesthetics unit, prompting the drugmaker to raise its full-year revenue forecast.

03 Aug 2017

UPDATE 1-Botox-maker Allergan's quarterly profit beats estimates

Aug 3 Botox-maker Allergan Plc reported a better-than-expected quarterly profit, helped by strength in its medical aesthetics unit, prompting the drugmaker to raise its full-year revenue forecast.

03 Aug 2017

Botox-maker Allergan quarterly revenue rises 9 pct

Aug 3 Drugmaker Allergan Plc posted a 9 percent rise in quarterly revenue, helped by strength in its medical aesthetics unit.

03 Aug 2017

BRIEF-Allergan Q3 cash dividend of $0.70/shr

* Allergan announces third quarter 2017 cash dividend of $0.70 per ordinary share Source text for Eikon: Further company coverage:

02 Aug 2017

BRIEF-Amgen and Allergan submit biosimilar Biologics License application for ABP 980 to U.S. FDA

* Amgen and Allergan submit biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration

31 Jul 2017

Earnings vs. Estimates